Overview
Desmoplastic fibromas, also known as desmoid tumors, are rare, locally aggressive neoplasms arising from connective tissue without distant metastasis 1.Diagnosis
Imaging studies (MRI, CT) essential for initial assessment and monitoring disease progression 1.
Biopsy confirms diagnosis through histopathological examination showing characteristic fibrous proliferation 1.
No standardized grading system; clinical behavior often guides management decisions 1.Management
First-line treatment: Nirogacestat, a selective gamma-secretase inhibitor, is approved for desmoid tumors 1.
Adjunctive treatments: Surgery (when feasible) and radiotherapy may be considered for localized disease or symptom control 1.
Management considerations: Close monitoring for adverse events, particularly gastrointestinal symptoms (diarrhea, nausea) and endocrine dysfunction (ovarian dysfunction, ovarian failure) 1.Special Populations
Pregnancy: Safety data limited; caution advised due to potential ovarian dysfunction risks 1.
Pediatrics: Specific pediatric data sparse; management typically follows adult guidelines with close monitoring 1.
Elderly: Consider comorbidities and functional status; risk-benefit analysis crucial for treatment decisions 1.
Comorbidities: Patients with endocrine-related comorbidities may require heightened vigilance for ovarian dysfunction and metabolic disturbances 1.Key Recommendations
Initiate nirogacestat as first-line therapy for symptomatic or growing desmoid tumors, balancing efficacy with gastrointestinal and endocrine adverse effects (Evidence: Moderate 1).
Regularly monitor patients for adverse events, particularly gastrointestinal symptoms and signs of ovarian dysfunction, given the high signal strength observed in FAERS data (Evidence: Strong 1).
Tailor management in special populations like pregnant women and the elderly based on individual risk assessment, considering limited specific data (Evidence: Expert opinion 1).References
1 Li Y, Yu L, Huang Y, Zeng Q, He Y, Liu L. Exploring Clinical Studies and the FDA Adverse Event Reporting System (FAERS) Database for nirogacestat-related Adverse Events. Therapeutic innovation & regulatory science 2025. link